tbuckley/cabot-search huggingface dataset:
Quantitative prediction of the bitterness of atomoxetine hydrochloride and taste-masked using hydroxypropyl-β-cyclodextrin: A biosensor evaluation and interaction study
Authors: Shuying Li, Ying Zhang, Abdur Rauf Khan, Shuwang He, Yingxin Wang, Jiangkang Xu, Guangxi Zhai
Journal: Asian Journal of Pharmaceutical Sciences (2019)

The bitterness of a drug is a major challenge for patient acceptability and compliance, especially for children. Due to the toxicity of medication, a human taste panel test has certain limitations. Atomoxetine hydrochloride (HCl), which is used for the treatment of attention deficit/hyperactivity disorder (ADHD), has an extremely bitter taste. The aim of this work is to quantitatively predict the bitterness of atomoxetine HCl by a biosensor system. Based on the mechanism of detection of the electronic tongue (E-tongue), the bitterness of atomoxetine HCl was evaluated, and it was found that its bitterness was similar to that of quinine HCl. The bitterness threshold of atomoxetine HCl was 8.61 µg/ml based on the Change of membrane Potential caused by Adsorption (CPA) value of the BT0 sensor. In this study, the taste-masking efficiency of 2-hydroxypropyl-β-cyclodextrin (HP-β-CyD) was assessed by Euclidean distances on a principle component analysis (PCA) map with the SA402B Taste Sensing System, and the host-guest interactions were investigated by differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), nuclear magnetic resonance (NMR) spectroscopy and scanning electron microscopy (SEM). Biosensor evaluation and characterization of the inclusion complex indicated that atomoxetine HCl could actively react with 2-hydroxypropyl-β-cyclodextrin.
Collecting and banking human milk
Authors: D P Davies, L Carroll, F Derbyshire
Journal: BMJ (1980)

discernible in Dr Trapido's data and we estimate that his para 1 and para 2 groups are significantly younger (55 7 and 55 5 years) than the nulliparous (58-9 years).To test these predictions we have pooled the 1742 patients described by Dr Trapido, by Dr Juret and his colleagues,' and by us.As the table shows, the results conform very closely to those expected.Age and parity in patients with breast cancer-pooled data Parity 0 1 2 3 4 >5 Mean age at presentation 59-1 58-1 55-2 55-8 57 0 59-0 No 464 336 381 268 139 154Mean age at presentation is only an indirect index of latency and large numbers are needed to minimise other factors such as differing ages at initiation and inherent tumour growth rates.We suggest that this accounts for the differences between the three studies.
Endoscopic ultrasound-directed transenteric ERCP (EDEE) in patients with postsurgical anatomy – novel but challenging
Authors: Mouen A. Khashab
Journal: Endoscopy (2019)

Endoscopic retrograde cholangiopancreatography (ERCP) is technically challenging in patients with postsurgical upper gastrointestinal anatomy and enteroscopy-guided ERCP (e-ERCP) is utilized in most of these patients for biliary access [1]. Procedural success is suboptimal, especially in patients with Roux-en-Y anatomy. In patients with a Roux-en-Y gastric bypass (RYGB), we use EUS-directed transgastric ERCP (EDGE) for access into the excluded stomach and subsequent ERCP using standard duodenoscopes and equipment [2]. Nonetheless, the EDGE procedure remains controversial because of the potential risk of a permanent gastro-gastric fistula. In our experience, this risk is very low but data are needed to confirm the long-term safety of EDGE [2].
Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Authors: A. Horinouchi, S. Suzuki, H. Kamata, A. Kaneko, T. Fujisawa, Y. Ueda, T. Enokida, K. Ito, S. Okano, H. Makabe, T. Kawasaki, M. Tahara
Journal: Annals of Oncology (2019)
Clinical utility of routine proteinuria evaluation in the treatment decisions of patients receiving bevacizumab for metastatic solid tumors: A retrospective study
Authors: J. Yeh, D. Frieze, R. Martins, L. Carr
Journal: Journal of Clinical Oncology (2009)

6599 Background: Bevacizumab is an anti-VEGF monoclonal antibody approved for use in metastatic breast, colorectal, and non-small cell lung cancer patients. In the pivotal Phase III clinical trials, Grade 3/4 proteinuria occurred in &lt;5% of patients. The manufacturer recommends monitoring for the development of proteinuria but does not provide specific recommendations, except to discontinue treatment if the patient develops nephrotic syndrome. This retrospective analysis describes the incidence, severity, and cost of routine proteinuria monitoring in patients with metastatic solid tumors. Methods: A retrospective chart review was performed in our institution from June 1, 2005 to November 30, 2007. Patients treated with bevacizumab and seen in the breast, lung, and gastrointestinal cancer clinics were included. The primary endpoints are the incidence and severity of elevated proteinuria and the frequency of changes in bevacizumab due to elevated proteinuria. The secondary endpoints include analysis of the cost of routine proteinuria monitoring and to describe the correlation of proteinuria with bevacizumab-induced hypertension and other patient co-morbidities. Results: 243 patients were included in the analysis. Only 1.2% (3 of 243) of patients developed Grade 3/4 proteinuria. One of these patients had prior chronic renal insufficiency, while the other two patients had hepatitis and hepatocellular carcinoma. Seven patients developed Grade 3/4 bevacizumab-induced hypertension, however this did not correspond with the development of proteinuria. Over $130,000 was charged to patients for monitoring of proteinuria. Conclusions: These results demonstrate that clinically significant proteinuria is rare and routine proteinuria monitoring is associated with high cost. [Table: see text] No significant financial relationships to disclose.
Attacks on Ebola sites in DRC leave four workers dead
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Four Ebola workers have been killed and five others injured during two attacks in eastern Democratic Republic of the Congo (DRC), the World Health Organization has reported.

The dead include a vaccination team member, two drivers, and a police officer. One WHO staff member was injured, as were people from the DRC Ministry of Health.

The attacks occurred overnight on a shared living camp …
The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study
Authors: Maeve A O'Reilly, Dinisha Govender, Ajay Vora, Sujith Samarasinghe, Asim Khwaja, Victoria Grandage, Anupama Rao, Phil Ancliff, Danny Cheng, Ben Carpenter, Stephen Daw, David O'Connor, Rachael Hough
Journal: Blood (2017)
Digital Media Use in Children
Authors: Dillon Browne, Darcy A. Thompson, Sheri Madigan
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease
Authors: Evandro D. Bezerra, Linde M Morsink, Megan Othus, Brent L Wood, Min Fang, Brenda M Sandmaier, Marco Last Mielcarek, H. Joachim Deeg, H Gary Schoch, Frederick R. Appelbaum, Roland B. Walter
Journal: Blood (2019)
Environmental correlates of chronic obstructive pulmonary disease in 96 779 participants from the UK Biobank: a cross-sectional, observational study
Authors: Chinmoy Sarkar, Bing Zhang, Michael Ni, Sarika Kumari, Sarah Bauermeister, John Gallacher, Chris Webster
Journal: The Lancet Planetary Health (2019)

The role of environmental exposures in chronic obstructive pulmonary disease (COPD) remains inconclusive. We examined the association between environmental exposures (PM2·5, greenness, and urbanicity) and COPD prevalence using the UK Biobank cohort data to identify key built environment correlates of COPD.In this cross-sectional, observational study we used baseline data for UK Biobank participants. Included participants were aged 39 years and older, white, had available spirometry data, and had complete data for phenotypes and exposures. COPD was defined by spirometry with the 2017 Global Initiative for Chronic Obstructive Lung Disease criteria. Environmental exposures were PM2·5 derived from monitoring data and interpolated using land-use regression at the participants' geocoded residential addresses. Built environment metrics of residential greenness were modelled in terms of normalised difference vegetation index from remotely sensed colour infrared data within a 500 m residential catchment, and an urbanicity index derived from spatial analyses and measured with a 1 km buffer around each participant's residential address. Logistic regression models examined the associations between environmental exposures and COPD prevalence adjusting for a range of confounders. Subgroup analyses by urbanicity and effect modification by white blood cell count as an inflammatory marker were also done.We assessed 96 779 participants recruited between April 4, 2006, and Oct 1, 2010, of which 5391 participants had COPD with a prevalence of 5·6%. Each 10 μg/m3 increment in ambient PM2·5 exposure at a participant's residential location was associated with higher odds of COPD (odds ratio 1·55, 95% CI 1·14-2·10). Among the built environment metrics, urbanicity was associated with higher odds of COPD (1·05, 1·01-1·08 per interquartile increment), whereas residential greenness was protective, being associated with lower odds of COPD (0·89, 0·84-0·93 for each interquartile increment in greenness). The results remained consistent in models of COPD defined as per lower limit of normal criteria. The highest quartile of white blood cell count was associated with lower lung function and higher COPD risk with a significant interaction between PM2·5 and white blood cell count only in the model of lung function (p=0·0003).In this study of the built environment and COPD, to our knowledge the largest done in the UK, we found that exposure to ambient PM2·5 and urbanicity were associated with a higher risk of COPD. Residing in greener areas, as measured by normalised difference vegetation index, was associated with lower odds of COPD, suggesting the potential value of urban planning and design in minimising or offsetting environmental risks for the prevention and management of COPD.University of Hong Kong, UK Biobank, and UK Economic & Social Research Council.
Challenges of developing a digital scribe to reduce clinical documentation burden
Authors: Juan C. Quiroz, Liliana Laranjo, Ahmet Baki Kocaballi, Shlomo Berkovsky, Dana Rezazadegan, Enrico Coiera
Journal: npj Digital Medicine (2019)

Abstract Clinicians spend a large amount of time on clinical documentation of patient encounters, often impacting quality of care and clinician satisfaction, and causing physician burnout. Advances in artificial intelligence (AI) and machine learning (ML) open the possibility of automating clinical documentation with digital scribes, using speech recognition to eliminate manual documentation by clinicians or medical scribes. However, developing a digital scribe is fraught with problems due to the complex nature of clinical environments and clinical conversations. This paper identifies and discusses major challenges associated with developing automated speech-based documentation in clinical settings: recording high-quality audio, converting audio to transcripts using speech recognition, inducing topic structure from conversation data, extracting medical concepts, generating clinically meaningful summaries of conversations, and obtaining clinical data for AI and ML algorithms.
Additional Factors in the Association of Gender and Parenthood With Conference Attendance
Authors: Yi-Ying Wu, Ren-Hua Ye, Tzu-Chuan Huang
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal–Organic Framework Nanoparticles to Boost Cancer Immunotherapy
Authors: Zhixiong Cai, Fuli Xin, Zuwu Wei, Ming Wu, Xinyi Lin, Xiaofan Du, Geng Chen, Da Zhang, Zhenxi Zhang, Xiaolong Liu, Cuiping Yao
Journal: Advanced Healthcare Materials (2019)

Abstract Photodynamic therapy (PDT) usually aggravates tumor hypoxia, which promotes the survival and metastasis of residue cancer cells; furthermore, although PDT‐induced immunogenic death of cancer cells can induce host antitumor responses, such responses are generally weak and not enough to eliminate the residue cancer cells. Here, metal–organic framework (MOF)‐based nanoparticles to combine PDT, antihypoxic signaling, and CpG adjuvant as an in situ tumor vaccine to boost host anticancer responses after PDT are designed. The MOF‐based nanoparticles are self‐assembled from H 2 TCPP and zirconium ions with hypoxia inducible factor (HIF) signaling inhibitor (ACF) and immunologic adjuvant (CpG) loading, and hyaluronic acid (HA) coating on the surface. The final nanoparticles (PCN‐ACF‐CpG@HA) can specifically target cancer cells overexpressing CD44 receptor though HA; the aggravated hypoxic survival signaling after PDT can be blocked by ACF to inhibit the HIF‐1α induced survival and metastasis. With the help of CpG adjuvant, the tumor associated antigens generated from PDT‐based cancer cell destruction can initiate strong antitumor immune responses to eliminate residue cancer cells. Taken together, a novel in situ immunostimulatory strategy is designed to synergistically enhance therapeutic effects of PDT by activating host antitumor immune‐responses both in vitro and in vivo, which may have great potential for clinical translation in future.
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer
Authors: Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu
Journal: Molecular Cancer (2019)

Abstract Background Long noncoding RNAs (lncRNAs) play nonnegligible roles in the epigenetic regulation of cancer cells. This study aimed to identify a specific lncRNA that promotes the colorectal cancer (CRC) progression and could be a potential therapeutic target. Methods We screened highly expressed lncRNAs in human CRC samples compared with their matched adjacent normal tissues. The proteins that interact with LINRIS (Long Intergenic Noncoding RNA for IGF2BP2 Stability) were confirmed by RNA pull-down and RNA immunoprecipitation (RIP) assays. The proliferation and metabolic alteration of CRC cells with LINRIS inhibited were tested in vitro and in vivo . Results LINRIS was upregulated in CRC tissues from patients with poor overall survival (OS), and LINRIS inhibition led to the impaired CRC cell line growth. Moreover, knockdown of LINRIS resulted in a decreased level of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), a newly found N 6 -methyladenosine (m 6 A) ‘reader’. LINRIS blocked K139 ubiquitination of IGF2BP2, maintaining its stability. This process prevented the degradation of IGF2BP2 through the autophagy-lysosome pathway (ALP). Therefore, knockdown of LINRIS attenuated the downstream effects of IGF2BP2, especially MYC-mediated glycolysis in CRC cells. In addition, the transcription of LINRIS could be inhibited by GATA3 in CRC cells. In vivo experiments showed that the inhibition of LINRIS suppressed the proliferation of tumors in orthotopic models and in patient-derived xenograft (PDX) models. Conclusion LINRIS is an independent prognostic biomarker for CRC. The LINRIS -IGF2BP2-MYC axis promotes the progression of CRC and is a promising therapeutic target.
Case settled of Irish student who developed narcolepsy after swine flu vaccine
Authors: Clare Dyer
Journal: BMJ (2019)

A legal claim against vaccine maker GlaxoSmithKline (GSK) and the Irish state by a student who developed severe narcolepsy after being vaccinated against swine flu has been settled by mediation after 21 days in the Irish High Court.

Aoife Bennett’s claim was settled for an undisclosed sum without admission of liability by either the state or GSK after running up costs of millions of euros. The Irish state, which like other countries gave GSK indemnity against legal action over the vaccine’s side effects, will pay the full compensation and all the …
Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients
Authors: Finola M. Bruins, Inge M. G. J. Bronckers, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong, Marieke M. B. Seyger
Journal: JAMA Dermatology (2019)

Treatment of psoriasis is associated with improved quality of life (QOL) in those with the disease. However, in daily clinical practice, the association between the degree of psoriasis clearance and QOL has not been studied to date, especially in the pediatric population.To identify the association between the degree of psoriasis improvement (as measured by the Psoriasis Area Severity Index [PASI] and body surface area [BSA] response) and QOL (as measured by the Children's Dermatology Life Quality Index [CDLQI]) in pediatric psoriasis, and to assess the association of treatment type with QOL, independent of psoriasis improvement.Data used in this single-center cohort study were extracted from the Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry), a prospective, observational, daily clinical practice cohort of all children (aged <18 years) with a psoriasis diagnosis who attended the outpatient clinic of the Department of Dermatology at the Radboud University Medical Center in Nijmegen, the Netherlands, between September 3, 2008, and May 4, 2018. All records of treatment episodes with CDLQI, PASI, and BSA scores were included in the analysis.Patients were treated according to daily clinical care. Treatments were clustered into topical, dithranol, conventional systemic, and biological treatments. Because of low numbers of UV-B phototherapy, this treatment was not assessed.Primary outcomes were mean change of CDLQI scores per PASI and BSA response categories (0 to <50, 50 to <75, 75 to <90, and ≥90) and mean CDLQI change per treatment categories.In total, 319 patients (median [interquartile range] age, 10.0 [7.0] years; 183 female [57.4%]) were analyzed for PASI score improvement (399 treatment episodes) and improvement in BSA involvement (366 treatment episodes). The greatest improvements in CDLQI scores were seen in the PASI ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.6 (95% CI, -7.5 to -5.7). The greatest improvements in CDLQI scores were also observed in the BSA ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.8 (95% CI, -7.5 to -6.1). Systemic treatment demonstrated a greater degree of improvement of CDLQI compared with topical treatment, independent of PASI response categories.This cohort study in a real-world setting found that the greatest improvements in QOL were associated with PASI 90 or greater, a decrease in BSA involvement of 90% or greater, and systemic treatments. These findings suggest that reaching PASI 90 or greater and decreasing BSA involvement by at least 90% may be clinically meaningful treatment goals that will help pediatric patients with psoriasis reach optimal QOL.